|
 |
Nanomedicine:
Newest Field of Science & Medicine |
 |
As
of 2006, the genetic, pharmaceutical, nutraceutical,
and food industries have embraced the newest and most
promising area of medicine. Nanomedicine is the science
of nanotechnology, which encompasses futuristic technology.
The term nanotechnology
is used to describe the interdisciplinary fields of
science devoted to the study of nanoscale phenomena
employed in nanotechnology. Spherical nanoparticles
are three dimensions on the nanoscale, i.e., the particle
is between 0.1 and 100 nm in each spatial dimension.
|
|
This
tiny world of chemistry has spun
into an entire industry of research in which nanoparticles
participate in all facets of medicine, including preventive
medicine.
The National
Institutes of Health (NIH) recently announced its Nanomedicine
Development Centers Awards that will share approximately $42-million
over five years. The four advanced centers in nanomedicine
are part of the NIH’s New Pathways to Discovery (www.Nano.gov).
The four centers are: The Center for Protein Folding Machinery
at Baylor College of Medicine; The National Center for Design
of Biomimetic Nanoconductors at the University of Illinois,
Urbana-Champaign; Engineering Cellular Control: Synthetic
Signaling and Motility Systems at the University of California,
San Francisco; and the Nanomedicine Center for Mechanical
Biology at Columbia University in New York (1).
Nanomedicine Development Centers will be established across
the country and will be staffed by multidisciplinary scientific
teams, including biologists, physicians, chemists, physicists,
mathematicians, engineers, and computer scientists. These
teams will conduct research and will train the next generation
of students in this new research area of medical science.
The new $84-million Molecular Foundry on the Lawrence Berkeley
National Laboratory (LBNL) campus in Berkeley, California
will allow scientists to begin making new types of nanoscale
material. |
|
 |
 |
New
Industrial Revolution |
 |
The
Nanotechnology revolution began in January 2000, when
U.S. President Bill Clinton requested a $227-million
increase in the government’s investment in nanotechnology
research and development.
This included a major initiative called the National
Nanotechnology Initiative (NNI) that nearly doubled
America’s budget investment in nanotechnology,
bringing the total invested in nanotechnology to $497-million
for the 2001 national budget
|
|
In
a written statement, White House officials said that…
“Nanotechnology is the new frontier and its potential
impact is compelling.”
About 70 percent of the new nanotechnology funding will go
to university research efforts, which will help meet the demand
for workers with nanoscale science and engineering skills.
The initiative will also fund the projects of several governmental
agencies, including the National Science Foundation, the Department
of Defense, the Department of Energy, the National Institutes
of Health, NASA and the National Institute of Standards and
Technology.
Nanotechnology is likely to change the way almost everything,
including medicine, computers and cars, are designed and constructed.
Nanotechnology-On-A-Chip
Nanotechnology-on-a-chip is one more dimension of lab-on-a-chip
technology. Biological tests measuring the presence or activity
of selected substances become quicker, more sensitive and
more flexible when certain nanoscale particles are put to
work as tags, labels, or carriers of agents in the body as
Edible Computer Chips.
Nanomanufacturing
Manufacturing at the nanoscale involves the industrial application
of nanotechnologies. Nanosize powder particles (nanoparticles)
can be engineered for applications in medicine and biotechnology.
L-ArginineM2® encompasses
the first proven technology for glycoside nanotechnology engineering.
The evolution of specific nanoparticles occurs during the
Trutina Dulcem 32-step process (www.TrutinaDulcem.com)
involving the removal of glycosides from organic kiwi fruit.
This technology provides the base for L-ArginineM2®. |
|
|
 |
 |
L-ArginineM2®
and Encode™ are currently utilized
in the genetic research field of Nutrigenomics
(www.GeneFoundation.com) as a carrier-mediated-transporter
in Sickle Cell disease, Alzheimer’s disease, Thalassemia,
Genetic Polymorphisms, Dysregulated Arginine Metabolism,
and generation of Pituitary Growth Hormone (GH).
Blood-Brain-Barrier
Transport
The components of L-ArginineM2®
are manufactured at the nanoscale (patents and patentspending)
which facilitates its ability to cross the Blood-Brain-Barrier
in humans.
|
|
Nanotechnology
& the Blood-Brain-Barrier
In its neuroprotective role, the Blood-Brain-Barrier (BBB)
blocks agents from entering the brain. Allowing therapeutic
agents to cross the BBB without allowing dangerous agents
access to the delicate brain-balance is a very intricate process
involving many years of specialized research in Blind Amino
Acid Transport Systems and Riders (BBB Carrier Transport Systems).
The key in Nanoengineering is to biochemically attach a therapeutic
agent combined with a nanoparticle in order to access one
of the four pathways. A nanosized agent is small enough to
cross the Blood-Brain-Barrier, as long as it is a “brain-friendly”
agent.
Since a nanoparticle is incredibly small, a delicate and complicated
proprietary process is required to produce L-ArginineM2
and its attendant “brain-friendly” glycosides,
which attach to an L-arginine molecule, thus transporting
it safely over the Blood-Brain-Barrier. Nanoparticles possess
a diameter small enough to penetrate through diminutive capillaries
into the cell’s internal machinery (2) and create a
pre-programmed response, thus the term Edible Computer Chip.
Nanoparticle Paths Of Entry
There are only four distinct paths of entry that allow nanoparticles
to enter the human body. L-ArginineM2 facilitates
access through endothelial-cell-gaps. These gaps allow L-ArginineM2
molecules to pass into the blood stream, where it is carried
throughout the body, and subsequently passed out of the blood
into diff erent tissues. In the brain, these endothelial cells
are packed more tightly together, due to the existence of
zonulae occludentes (tight junctions) between them, blocking
the passage of most molecules. |
|
|
|
L-Arginine
Transport
Only a specific transport system will allow the amino acid
L-arginine to cross the Blood-Brain-Barrier. L-ArginineM2®
plant glycosides are engineered to cross the Blood-Brain Barrier,
providing a carrier-mediated-transporter for the Blind Amino
Acid L-arginine, with specific function in nanoparticle biostrategy.
Reverse Engineering
L-ArginineM2®’s
bioengineering process defies reverse-engineering. It is currently
impossible to “copy” or duplicate L-ArginineM2®
nanotechnology due to the complexity of the development process.
Clinical Trials
The carrier-mediated-transporter system in L-ArginineM2®
has undergone Human In Vivo Clinical Trials in adults, children,
and diabetics, focusing on glycemic response, human adipose
tissue fat-storage, Lipoprotein Lipase (LPL), and blood glucose/insulin
response.
Nano-Future
The future of nanotechnology has vast implications for future
generations.
L-ArginineM2®
is
the first generation of scientific breakthroughs in nanotechnology
and nutrigenomics. The Encode Research Team (www.GeneFoundation.com)
is dedicated to developing and patenting an entire line of
low glycemic nutrigenomic products based on nanotechnology.
The Encode Research Team is planning on introducing the next
generation of patented Edible Computer Chips in 2007, including
“Chocolate Computer Chips”, fat-burning thermogenic
energy drinks, low glycemic candies for children that reduces
risk of diabetes, and a sports drink that actually biochemically
improves sports performance.
For more information on Nanotechnology, visit www.EdibleComputerChips.com
and the United States government website www.nano.gov |
|
|
 |
| |
|
“Science without religion
is lame and,
conversely, religion without science is blind.
Both are important and should work hand-in-hand”
Albert Einstein
Theory of Relativity
E=MC²
Nobel Prize in Physics
L-ArginineM²
was named in honor of
Albert Einstein
|
|
|
|
 |
Albert
Einstein College of Medicine Enters Nanobio
Alliance with University of Albany College of
Nanoscale Science & Engineering |
|
The
Albert Einstein College of Medicine of
Yeshiva University and the College of Nanoscale Science and
Engineering (CNSE) of the University at Albany-State University
of New York announced a new partnership to advance education
and research in the cross-disciplinary fields of nanobiotechnology
and nanomedicine.
The
joint research thrusts focus on investigating and optimizing
the interface between the world of biology and the world of
nanofabrication to develop "bio-systems on
a chip" (B-SOCs) for medical and biomedical
applications.
The
partnership will bring together the unique expertise and resources
of both institutions to focus on the nanoscale principles
and their application to disease identification and treatment
development. CNSE is based at Albany NanoTech,
one of the largest global centers of nanoscale
scientific research with the most extensive nanotechnology
facilities in the academic world. Albert Einstein College
of Medicine, one of the nation’s top medical schools,
receives more than $150 million annually in federal support
for innovative medical research.
"We
are excited to be entering into this strategic partnership
with one of the premier medical colleges in the world, particularly
as we ramp up our nanobiotechnology
research and education initiatives," said Alain Kaloyeros,
Ph.D., Vice President and Chief Administrative Officer of
CNSE and President of Albany NanoTech. "Nanotechnology
holds enormous promise for revolutionizing many areas of our
lives, but none more promising than disease identification
and treatment. We look forward to collaborating with the distinguished
physicians, scientists, and students of the Albert Einstein
College of Medicine on some of the most potentially exciting
applications for nanoscale scientific
concepts and tools."
These
statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose,
treat, cure or prevent any disease.
|
L-ArginineM2®
is backed by a registered federal government Patent,
Patents-Pending, and two decades of L-Arginine Research
|
Illegal
copying of this material is a Federal Offense and violators
will be prosecuted |
|
|
|
|
